168215

Scientific & Technical Information Center

Online Database Search Form

MEJ

Search requests relating to published applications, patent families, and litigation can b
form and clicking on "Send."

SERVICES
Database Search submit
PLUS Search submit
Book/Article Delivery submit
Book/Journal Purchase submit
Foreign Patents submit
Telework Support
Translation submit
SIRA Automation Training
STIC Demos & Events

RESOURCES
STIC Online Catalog
Databases
E-Books search
E-Journals search
Legal Tools
Nanotechnology
Reference Tools

STIC
About Us
FAQ
Locations & Hours
News
Site Map
Staff

Search STIC Site
GO

Tech Center:

(•) TC 1600 ( ) TC 1700 ( ) TC 2100 ( ) TC 2600 ( ) TC 2800
( ) TC 2900 ( ) TC 3600 ( ) TC 3700 ( ) Law Lib ( ) Other

Your Contact Information:
* indicates mandatory information.

1+ amndt

Your Name: TAMTHOM N. TRUONG
*Email Address: tamthom.ngo@uspto.gov
(e.g., Susan.Smith@uspto.gov)
*Employee No.: 74142
*Art Unit/Org.: 1624
*Office Location: REM -- 5B19
*Phone No.: x 20676
Mailbox No.: REM -- 5C18

***Case serial number:** 09/ 806,836
If not related to a patent application, please enter NA here.

Class / Subclass(es): 514/266.1 & 544/284

Earliest Priority Filing Date: 10-08-1998

RECEIVED
OCT 11 2005
TECH CENTER 1600/2900
STIC

Format preferred for results:
[x] Paper [ ] Diskette [ ] E-mail

Provide detailed information on your search topic:

- In your own words, describe in detail the concepts or subjects you want us to se
- Include synonyms, keywords, and acronyms. Define terms that have special me
- *For Chemical Structure Searches Only*
  Include the elected species or structures, keywords, synonyms, acronyms, and
- *For Sequence Searches Only*
  Include all pertinent information (parent, child, divisional, or issued patent numb
  serial number.
- *For Foreign Patent Family Searches Only*
  Include the country name and patent number.

9/806,836 Query



Zb is -O-, or -S-

Ring C is 5-6 mem. heterocyclic moiety sat'd or unsat'd, aromatic or non-aromatic, & contains 1-3 heteroatoms selected from O, N & S.

See also claims 10-13 (species) & claim 18

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

CONFIRMATION NO. 6411

Bib Data Sheet

SERIAL NUMBER	FILING DATE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO.
09/806,836	06/12/2001 RULE	514	1624	P.278065

APPLICANTS

14 amdt

Laurent F A Hennequin, Reims, FRANCE;

Georges Pasquet, Reims, FRANCE;

** CONTINUING DATA **********
This application is a 371 of PCT/GB99/03295 10/05/1999

** FOREIGN APPLICATIONS **********
EUROPEAN PATENT OFFICE (EPO) 98402496.8 10/08/1998

Foreign Priority claimed ☐ yes ☐ no 35 USC 119 (a-d) conditions met ☐ yes ☐ no ☐ Met after Allowance Verified and Acknowledged Examiner's Signature Initials	STATE OR COUNTRY FRANCE	SHEETS DRAWING	TOTAL CLAIMS 17	INDEPENDENT CLAIMS 1

ADDRESS
09629
MORGAN LEWIS & BOCKIUS LLP
1111 PENNSYLVANIA AVENUE NW
WASHINGTON , DC
20004

TITLE
Quinazoline derivatives

FILING FEE	FEES: Authority has been given in Paper
RECEIVED 1638	No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:

☐ All Fees
☐ 1.16 Fees (Filing)
☐ 1.17 Fees (Processing Ext. of time)
☐ 1.18 Fees (Issue)

		☐ Other _____
		☐ Credit

14) 1-($R^{29}X^8$)but-2-yn-4-yl (wherein X^8 and R^{29} are as defined in claim 18);

15) C_{2-3}alkylX^9C_{1-2}alkylR^{29} (wherein X^9 and R^{29} are as defined in claim 18);

16) R^{28} (wherein R^{28} is as defined in claim 18);

17) C_{2-3}alkylX^9C_{1-2}alkylR^{28} (wherein X^9 and R^{28} are as defined in claim 18); and

18) C_{2-3}alkyl$R^{54}C_{1-2}$alkylX^9R^{55} (wherein X^9, R^{54} and R^{55} are as defined in claim 18);

and additionally wherein any C_{1-5}alkyl, C_{2-5}alkenyl or C_{2-5}alkynyl group in R^5X^1- may bear one or more substituents selected from hydroxy, halogeno and amino.

Claim 10 (**previously presented**): A compound as claimed in claim 18 wherein R^2 represents 2-methoxyethoxy, 2-(2-methoxyethoxy)ethoxy, 3-methoxypropoxy, 2-methylsulphonylethoxy, 3-methylsulphonylpropoxy, 2-(tetrahydropyran-4-yloxy)ethoxy, 3-(tetrahydropyran-4-yloxy)propoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-(imidazol-1-yl)ethoxy, 3-(imidazol-1-yl)propoxy 2-(1,1-dioxothiomorpholino)ethoxy, 3-(1,1-dioxothiomorpholino)propoxy, 2-(1,2,3-triazol-1-yl)ethoxy, 3-(1,2,3-triazol-1-yl)propoxy, 2-(N-methoxyacetyl-N-methylamino)ethoxy, 3-(N-methoxyacetyl-N-methylamino)propoxy, N-methylpiperidin-3-ylmethoxy, 4-(pyrrolidin-1-yl)but-2-en-yloxy, 2-(2-oxopyrrolidin-1-yl)ethoxy, 3-(2-oxopyrrolidin-1-yl)propoxy, 2-(pyrrolidin-1-yl)ethoxy, 3-(pyrrolidin-1-yl)propoxy, 2-(2-(pyrrolidin-1-yl)ethoxy)ethoxy, 2-(2-(4-methylpiperazin-1-yl)ethoxy)ethoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, 2-(methylpiperidino)ethoxy, 3-(methylpiperidino)propoxy, 2-(ethylpiperidino)ethoxy, 3-(ethylpiperidino)propoxy, 2-((2-methoxyethyl)piperidino)ethoxy, 3-((2-methoxyethyl)piperidino)propoxy, 2-((2-methylsulphonyl)ethylpiperidino)ethoxy, 3-((2-methylsulphonyl)ethylpiperidino)propoxy, piperidin-3-ylmethoxy, piperidin-4-ylmethoxy, 2-(piperidin-3-yl)ethoxy, 2-(piperidin-4-yl)ethoxy, 3-(piperidin-3-yl)propoxy, 3-(piperidin-4-yl)propoxy, 2-(methylpiperidin-3-yl)ethoxy, 2-(methylpiperidin-4-yl)ethoxy, 3-(methylpiperidin-3-yl)propoxy, 3-(methylpiperidin-4-yl)propoxy, 2-(ethylpiperidin-3-yl)ethoxy,

2-(ethylpiperidin-4-yl)ethoxy, 3-(ethylpiperidin-3-yl)propoxy,
3-(ethylpiperidin-4-yl)propoxy, 2-((2-methoxyethyl)piperidin-3-yl)ethoxy,
2-((2-methoxyethyl)piperidin-4-yl)ethoxy, 3-((2-methoxyethyl)piperidin-3-yl)propoxy,
3-((2-methoxyethyl)piperidin-4-yl)propoxy,
2-((2-methylsulphonylethyl)piperidin-3-yl)ethoxy,
2-((2-methylsulphonylethyl)piperidin-4-yl)ethoxy,
3-((2-methylsulphonylethyl)piperidin-3-yl)propoxy,
3-((2-methylsulphonylethyl)piperidin-4-yl)propoxy, 1-isopropylpiperidin-2-ylmethyl,
1-isopropylpiperidin-3-ylmethyl, 1-isopropylpiperidin-4-ylmethyl,
2-(1-isopropylpiperidin-2-yl)ethyl, 2-(1-isopropylpiperidin-3-yl)ethyl,
2-(1-isopropylpiperidin-4-yl)ethyl, 3-(1-isopropylpiperidin-2-yl)propyl,
3-(1-isopropylpiperidin-3-yl)propyl, 3-(1-isopropylpiperidin-4-yl)propyl,
3-(4-methylpiperazin-1-yl)propoxy, 1-methylpiperidin-4-ylmethoxy,
1-(2-methylsulphonylethyl)piperidin-4-ylmethoxy,
1-(2-pyrrolidinylethyl)piperidin-4-ylmethoxy,
1-(3-pyrrolidinylpropyl)piperidin-4-ylmethoxy, 1-(2-piperidinylethyl)piperidin-4-ylmethoxy,
1-(3-piperidinylpropyl)piperidin-4-ylmethoxy, 1-(2-morpholinoethyl)piperidin-4-ylmethoxy,
1-(3-morpholinopropyl)piperidin-4-ylmethoxy,
1-(2-thiomorpholinoethyl)piperidin-4-ylmethoxy,
1-(3-thiomorpholinopropyl)piperidin-4-ylmethoxy,
1-(2-azetidinylethyl)piperidin-4-ylmethoxy or 1-(3-azetidinylpropyl)piperidin-4-ylmethoxy.

Claim 11 (**previously presented**): A compound as claimed in claim 18 selected from:
4-(5-(4-methoxyphenyl)pyrazol-3-yloxy)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)-quinazoline,
4-(5-(4-methoxyphenyl)pyrazol-3-yloxy)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)-propoxy)quinazoline,
6-methoxy-7-(2-(2-methoxyethoxy)ethoxy)-4-(5-phenylpyrazol-3-yloxy)quinazoline,
4-(5-(3-furyl)pyrazol-3-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,

6-methoxy-7-(3-morpholinopropoxy)-4-(5-phenylpyrazol-3-yloxy)quinazoline,
7-(2-(imidazol-1-yl)ethoxy)-6-methoxy-4-(5-phenylpyrazol-3-yloxy)quinazoline,
4-(5-(4-chlorophenyl)pyrazol-3-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,
6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)-4-(5-phenylpyrazol-3-yloxy)-quinazoline,
6-methoxy-7-(2-methoxyethoxy)-4-(5-phenylpyrazol-3-yloxy)quinazoline,
4-(5-(4-methoxyphenyl)pyrazol-3-yloxy)-6-methoxy-7-(2-(1,2,3-triazol-1-yl)ethoxy)-quinazoline and
4-(5-(4-methoxyphenyl)pyrazol-3-yloxy)-6-methoxy-7-(1-(2-methylsulphonylethyl)-piperidin-4-ylmethoxy)quinazoline,
and salts thereof.

Claim 12 (**previously presented**): A compound as claimed in claim 18 selected from:
7-(2-methoxyethoxy)-4-(5-phenylpyrazol-3-yloxy)quinazoline,
4-(5-(2-fluorophenyl)pyrazol-3-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,
6-methoxy-7-(3-morpholinopropoxy)-4-(5-(3-nitrophenyl)pyrazol-3-yloxy)quinazoline,
6-methoxy-7-(3-morpholinopropoxy)-4-(5-(4-nitrophenyl)pyrazol-3-yloxy)quinazoline,
6-methoxy-7-(3-morpholinopropoxy)-4-(5-(4-pyridyl)pyrazol-3-yloxy)quinazoline,
4-(5-(4-fluorophenyl)pyrazol-3-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline, and
6-methoxy-7-(2-methoxyethoxy)-4-(5-(4-methoxyphenyl)pyrazol-3-yloxy)quinazoline,
and salts thereof.

Claim 13 (**previously presented**): A method for producing an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal in need of such treatment which comprises administering to such animal an effective amount of a compound selected from the group consisting of:
6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)-4-(5-phenylpyrazol-3-ylamino)-quinazoline and
6,7-dimethoxy-4-(5-phenylpyrazol-3-yloxy)quinazoline
and pharmaceutically acceptable salts thereof.

Claim 14 (**previously presented**): A compound as claimed in any one of claims 18 and 5 to 12 in the form of a pharmaceutically acceptable salt.

Claim 15 (**cancelled**).

Claim 16 (**previously presented**): A pharmaceutical composition which comprises as active ingredient a compound of formula II or a pharmaceutically acceptable salt thereof as claimed in any one of claims 18 and 5 to 12 in association with a pharmaceutically acceptable excipient or carrier.

Claim 17 (**previously presented**): A method for producing an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal in need of such treatment which comprises administering to said animal an effective amount of a compound of formula II as defined in any one of claims 18 and 5 to 12 or a pharmaceutically acceptable salt thereof.

Claim 18 (**currently amended**): A compound of the formula II:



II

wherein:

ring C is a 5-6-membered heterocyclic moiety which may be saturated or unsaturated, which may be aromatic or non-aromatic, and which contains 1-3 heteroatoms selected independently from O, N and S;

Zb is –O- or –S-;

R^1 represents hydrogen, C_{1-4}alkyl, C_{1-4}alkoxymethyl, di(C_{1-4}alkoxy)methyl, C_{1-4}alkanoyl, trifluoromethyl, cyano, amino, C_{2-5}alkenyl, C_{2-5}alkynyl, a phenyl group, a benzyl group or a 5-6-membered heterocyclic group with 1-3 heteroatoms, selected independently from O, S and N, which heterocyclic group may be aromatic or non-aromatic and may be saturated ~~(linked~~ and linked via a ring carbon or nitrogen atom, ~~atom)~~ or unsaturated ~~(linked~~ and linked via a ring carbon atom, ~~atom),~~ and which phenyl, benzyl or heterocyclic group may bear on one or more ring carbon atoms up to 5 substituents selected from hydroxy, halogeno, C_{1-3}alkyl, C_{1-3}alkoxy, C_{1-3}alkanoyloxy, trifluoromethyl, cyano, amino, nitro, C_{2-4}alkanoyl, C_{1-4}alkanoylamino, C_{1-4}alkoxycarbonyl, C_{1-4}alkylsulphanyl, C_{1-4}alkylsulphinyl, C_{1-4}alkylsulphonyl, carbamoyl, N-C_{1-4}alkylcarbamoyl, N,N-di(C_{1-4}alkyl)carbamoyl, aminosulphonyl, N-C_{1-4}alkylaminosulphonyl, N,N-di(C_{1-4}alkyl)aminosulphonyl, C_{1-4}alkylsulphonylamino, C_{1-4}alkylamino, C_{1-4}hydroxyalkyl, C_{1-4}aminoalkyl, C_{1-4}haloalkyl, C_{1-4}hydroxyalkoxy, carboxy and a saturated heterocyclic group selected from morpholino, thiomorpholino, pyrrolidinyl, piperazinyl, piperidinyl imidazolidinyl and pyrazolidinyl, which saturated heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, C_{1-3}alkyl, C_{1-3}alkoxy, C_{1-3}alkanoyloxy, trifluoromethyl, cyano, amino, nitro and C_{1-4}alkoxycarbonyl; and additionally R^1 may represent carboxy, C_{3-7}cycloalkyl, C_{3-7}cycloalkylC_{1-3}alkyl, or phenylC_{2-4}alkyl wherein the phenyl moiety may bear up to 5 substituents selected from the list herein defined for a phenyl ring which is directly linked to ring C;

n is an integer from 0 to 5;

m is an integer from 0 to 3;

R^2 represents hydroxy, cyano, nitro, trifluoromethyl, C_{1-3}alkylsulphanyl, $-NR^3R^4$ ~~(wherein,~~ wherein R^3 and R^4, which may be the same or different, each represents hydrogen or ~~C_{1-3}alkyl),~~ C_{1-3}alkyl,

or R^2 represents R^5X^1 ~~(wherein,~~ wherein X^1 represents a direct bond, -O-, $-CH_2-$, -OCO-, carbonyl, -S-, -SO-, $-SO_2-$, $-NR^6CO-$, $-CONR^7-$, $-SO_2NR^8-$, $-NR^9SO_2-$ or $-NR^{10}-$ ~~(wherein,~~ wherein R^6, R^7, R^8, R^9 and R^{10} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl~~), and,~~ and R^5 is selected from one of the following eighteen groups:

1) hydrogen or C_{1-5}alkyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, chloro, bromo and amino;

2) C_{1-5}alkylX^2COR^{11} ~~(wherein,~~ wherein X^2 represents -O- or $-NR^{12}-$ ~~(in which,~~ in which R^{12} represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl~~) and,~~ and R^{11} represents C_{1-3}alkyl, $-NR^{13}R^{14}$ or $-OR^{15}$ ~~(wherein,~~ wherein R^{13}, R^{14} and R^{15} which may be the same or different each represents hydrogen, C_{1-3}alkyl, C_{4-5}alkyl or C_{1-3}alkoxyC_{2-3}alkyl~~)~~);

3) C_{1-5}alkylX^3R^{16} ~~(wherein,~~ wherein X^3 represents -O-, -S-, -SO-, $-SO_2-$, -OCO-, $-NR^{17}CO-$, $-CONR^{18}-$, $-SO_2NR^{19}-$, $-NR^{20}SO_2-$ or $-NR^{21}-$ ~~(wherein,~~ wherein R^{17}, R^{18}, R^{19}, R^{20} and R^{21} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl~~) and,~~ and R^{16} represents hydrogen, C_{1-3}alkyl, cyclopentyl, cyclohexyl or a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which C_{1-3}alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C_{1-4}alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}cyanoalkyl and ~~C_{1-4}alkoxycarbonyl)~~ C_{1-4}alkoxycarbonyl;

4) C_{1-5}alkylX^4C_{1-5}alkylX^5R^{22} ~~(wherein,~~ wherein X^4 and X^5 ~~which,~~ which may be the same or different ~~are,~~ are each -O-, -S-, -SO-, $-SO_2-$, $-NR^{23}CO-$, $-CONR^{24}-$, $-SO_2NR^{25}-$, $-NR^{26}SO_2-$ or $-NR^{27}-$ ~~(wherein,~~ wherein R^{23}, R^{24}, R^{25}, R^{26} and R^{27} each

independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl~~) and~~, and R^{22} represents hydrogen, C_{1-3}alkyl or ~~C_{1-3}alkoxyC_{2-3}alkyl)~~ C_{1-3}alkoxyC_{2-3}alkyl;

5) R^{28} ~~(wherein,~~ wherein R^{28} is a 5-6-membered saturated heterocyclic group ~~(linked,~~ linked via carbon or nitrogen~~) with~~, with 1-2 heteroatoms~~, selected~~ selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkylsulphonylC_{1-4}alkyl and ~~C_{1-4}alkoxycarbonyl)~~ C_{1-4}alkoxycarbonyl;

6) C_{1-5}alkylR^{28} ~~(wherein,~~ wherein R^{28} is as defined ~~herein)~~ herein;

7) C_{2-5}alkenylR^{28} ~~(wherein,~~ wherein R^{28} is as defined ~~herein)~~ herein;

8) C_{2-5}alkynylR^{28} ~~(wherein,~~ wherein R^{28} is as defined ~~herein)~~ herein;

9) R^{29} ~~(wherein,~~ wherein R^{29} represents a pyridone group, a phenyl group or a 5-6-membered aromatic heterocyclic group ~~(linked,~~ linked via carbon or nitrogen~~) with~~, with 1-3 heteroatoms selected from O, N and S, which pyridone, phenyl or aromatic heterocyclic group may carry up to 5 substituents on an available carbon atom selected from hydroxy, halogeno, amino, C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4}hydroxyalkyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, C_{1-4}hydroxyalkoxy, carboxy, trifluoromethyl, cyano, $-CONR^{30}R^{31}$ and $-NR^{32}COR^{33}$ ~~(wherein,~~ wherein R^{30}, R^{31}, R^{32} and R^{33}, which may be the same or different, each represents hydrogen, C_{1-4}alkyl or C_{1-3}alkoxyC_{2-3}alkyl~~)~~);

10) C_{1-5}alkylR^{29} ~~(wherein,~~ wherein R^{29} is as defined ~~herein)~~ herein;

11) C_{2-5}alkenylR^{29} ~~(wherein,~~ wherein R^{29} is as defined ~~herein)~~ herein;

12) C_{2-5}alkynylR^{29} ~~(wherein,~~ wherein R^{29} is as defined ~~herein)~~ herein;

13) C_{1-5}alkylX^6R^{29} ~~(wherein,~~ wherein X^6 represents -O-, -S-, -SO-, $-SO_2-$, $-NR^{34}CO-$, $-CONR^{35}-$, $-SO_2NR^{36}-$, $-NR^{37}SO_2-$ or $-NR^{38}-$ ~~(wherein,~~ wherein R^{34}, R^{35}, R^{36}, R^{37} and R^{38} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl~~) and~~, and R^{29} is as defined ~~herein)~~ herein;

14) C_{2-5}alkenylX^7R^{29} ~~(wherein,~~ wherein X^7 represents -O-, -S-, -SO-, $-SO_2-$, $-NR^{39}CO-$, $-CONR^{40}-$, $-SO_2NR^{41}-$, $-NR^{42}SO_2-$ or $-NR^{43}-$ ~~(wherein,~~ wherein R^{39}, R^{40}, R^{41}, R^{42} and

R^{43} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl~~) and~~, and R^{29} is as defined ~~herein)~~ herein;

15) C_{2-5}alkynylX^8R^{29} ~~(wherein~~, wherein X^8 represents -O-, -S-, -SO-, $-SO_2-$, $-NR^{44}CO-$, $-CONR^{45}-$, $-SO_2NR^{46}-$, $-NR^{47}SO_2-$ or $-NR^{48}-$ ~~(wherein~~, wherein R^{44}, R^{45}, R^{46}, R^{47} and R^{48} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl~~) and~~, and R^{29} is as defined ~~herein)~~ herein;

16) C_{1-3}alkylX^9C_{1-3}alkylR^{29} ~~(wherein~~, wherein X^9 represents -O-, -S-, -SO-, $-SO_2-$, $-NR^{49}CO-$, $-CONR^{50}-$, $-SO_2NR^{51}-$, $-NR^{52}SO_2-$ or $-NR^{53}-$ ~~(wherein~~, wherein R^{49}, R^{50}, R^{51}, R^{52} and R^{53} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl~~) and~~, and R^{29} is as defined ~~herein)~~ herein;

17) C_{1-3}alkylX^9C_{1-3}alkylR^{28} ~~(wherein~~, wherein X^9 and R^{28} are as defined ~~herein)~~ herein; and

18) C_{1-3}alkyl$R^{54}C_{1-3}$alkylX^9R^{55} ~~(wherein~~, wherein X^9 is as defined herein and R^{54} and R^{55} are each independently selected from hydrogen, C_{1-3}alkyl, cyclopentyl, cyclohexyl and a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which C_{1-3}alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C_{1-4}alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}cyanoalkyl and C_{1-4}alkoxycarbonyl~~), with~~, with the proviso that R^{54} cannot be hydrogen;

and additionally wherein any C_{1-5}alkyl, C_{2-5}alkenyl or C_{2-5}alkynyl group in R^5X^1- may bear one or more substituents selected from hydroxy, halogeno and amino; provided that R^2 is not hydrogen, substituted or unsubstituted C_{1-5}alkyl, C_{1-5}alkoxy, phenoxy or phenylC_{1-5}alkoxy; and

R^{2a} represents hydrogen, halogeno, C_{1-3}alkyl, C_{1-3}alkoxy, C_{1-3}alkylthio, $-NR^{3a}R^{4a}$ ~~(wherein~~, wherein R^{3a} and R^{4a}, which may be the same or different, each represents hydrogen or C_{1-3}alkyl~~), or~~, or $R^{5a}(CH_2)_{za}X^{1a}$ ~~(wherein~~, wherein R^{5a} is a 5- or 6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno,

C_{1-4}alkyl, C_{1-4}hydroxyalkyl and C_{1-4}alkoxy, za is an integer from 0 to 4 and X^{1a} represents a direct bond, -O-, $-CH_2-$, -S-, -SO-, $-SO_2-$, $-NR^{6a}CO-$, $-CONR^{7a}-$, $-SO_2NR^{8a}-$, $-NR^{9a}SO_2-$ or $-NR^{10a}$ ~~(wherein,~~ wherein R^{6a}, R^{7a}, R^{8a}, R^{9a} and R^{10a} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl~~)~~;

or a salt thereof.

19 (**previously presented**): A process for the preparation of a compound of formula II or salt thereof, as defined in claim 18, which comprises:

(a) the reaction of a compound of the formula III:



(III)

(wherein R^2 and m are as defined in claim 18 and L^1 is a displaceable moiety), with a compound of the formula IV:



(IV)

(wherein ring C, R^1, Z and n are as defined in claim 18);

168215

Scientific & Technical Information Center

SERVICES
Database Search submit
PLUS Search submit
Book/Article Delivery submit
Book/Journal Purchase submit
Foreign Patents submit
Telework Support
Translation submit
SIRA Automation Training
STIC Demos & Events

RESOURCES
STIC Online Catalog
Databases
E-Books search
E-Journals search
Legal Tools
Nanotechnology
Reference Tools

STIC
About Us
FAQ
Locations & Hours
News
Site Map
Staff

Search STIC Site
GO

Online Database Search Form

ME

Search requests relating to published applications, patent families, and litigation can b
form and clicking on "Send."

Tech Center:

(•) TC 1600 ( ) TC 1700 ( ) TC 2100 ( ) TC 2600 ( ) TC 2800
( ) TC 2900 ( ) TC 3600 ( ) TC 3700 ( ) Law Lib ( ) Other

Your Contact Information:
* indicates mandatory information.

Your Name: TAMTHOM N. TRUONG
*Email Address: tamthom.ngo@uspto.gov
(*e.g., Susan.Smith@uspto.gov*)
*Employee No.: 74142
*Art Unit/Org.: 1624
*Office Location: REM -- 5B19
*Phone No.: x 20676
Mailbox No.: REM -- 5C18

1+ amdt

***Case serial number:** 09/ 806,836
If not related to a patent application, please enter NA here.

Class / Subclass(es) 514/266.1 & 544/284

Earliest Priority Filing Date: 10-08-1998

RECEIVED
OCT 11 2005
TECHNOLOGY CENTER 1600

Format preferred for results:
☑ Paper ☐ Diskette ☐ E-mail

Provide detailed information on your search topic:

- In your own words, describe in detail the concepts or subjects you want us to se
- Include synonyms, keywords, and acronyms. Define terms that have special me
- *For Chemical Structure Searches Only*
  Include the elected species or structures, keywords, synonyms, acronyms, and
- *For Sequence Searches Only*
  Include all pertinent information (parent, child, divisional, or issued patent numb
  serial number.
- *For Foreign Patent Family Searches Only*
  Include the country name and patent number.